Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cédric Louvet, Gregory L. Szot, Jiena Lang, et al.
Proceedings of the National Academy of Sciences (2008) Vol. 105, Iss. 48, pp. 18895-18900
Open Access | Times Cited: 214

Showing 51-75 of 214 citing articles:

Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
Keiko Ono, Hitoshi Suzushima, Yuko Watanabe, et al.
Internal Medicine (2012) Vol. 51, Iss. 19, pp. 2763-2766
Closed Access | Times Cited: 49
Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia
Rongras Damrongwatanasuk, Michael G. Fradley
Current Treatment Options in Cardiovascular Medicine (2017) Vol. 19, Iss. 4
Closed Access | Times Cited: 48
Genistein Protects Female Nonobese Diabetic Mice from Developing Type 1 Diabetes When Fed a Soy- and Alfalfa-free Diet
Tai L. Guo, Dori R. Germolec, Jian Feng Zheng, et al.
Toxicologic Pathology (2014) Vol. 43, Iss. 3, pp. 435-448
Open Access | Times Cited: 43
Endoplasmic reticulum stress in pancreatic β-cell dysfunction: The potential therapeutic role of dietary flavonoids
Kingsley C. Mbara, Marthe Carine Djuidje Fotsing, Derek Tantoh Ndinteh, et al.
Current Research in Pharmacology and Drug Discovery (2024) Vol. 6, pp. 100184-100184
Open Access | Times Cited: 4
Saracatinib, a Src kinase inhibitor, enhances the renoprotective effect of metformin and losartan in diabetic nephropathy
Suzan A Khodir, Eman Sweed, Mona A. Kora, et al.
Archives of Physiology and Biochemistry (2025), pp. 1-16
Closed Access
Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?
Stephen Fitter, Kate Vandyke, Christopher G. Schultz, et al.
The Journal of Clinical Endocrinology & Metabolism (2010) Vol. 95, Iss. 8, pp. 3763-3767
Closed Access | Times Cited: 53
An update on the use of NOD mice to study autoimmune (Type 1) diabetes
Rodolfo Chaparro, Teresa P. DiLorenzo
Expert Review of Clinical Immunology (2010) Vol. 6, Iss. 6, pp. 939-955
Open Access | Times Cited: 52
Immune intervention in type 1 diabetes
Aaron W. Michels, George S. Eisenbarth
Seminars in Immunology (2011) Vol. 23, Iss. 3, pp. 214-219
Open Access | Times Cited: 47
The Non-Obese Diabetic (NOD) Mouse as a Model of Human Type 1 Diabetes
Kritika Kachapati, David H. Adams, Kyle J. Bednar, et al.
Methods in molecular biology (2012), pp. 3-16
Closed Access | Times Cited: 46
AMP-dependent Kinase Inhibits Oxidative Stress-induced Caveolin-1 Phosphorylation and Endocytosis by Suppressing the Dissociation between c-Abl and Prdx1 Proteins in Endothelial Cells
Kimio Takeuchi, Yuki Morizane, Cynthia Kamami-Levy, et al.
Journal of Biological Chemistry (2013) Vol. 288, Iss. 28, pp. 20581-20591
Open Access | Times Cited: 41
Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin
Yoshikiyo Ito, Toshihiro Miyamoto, Yong Chong, et al.
International Journal of Hematology (2012) Vol. 97, Iss. 1, pp. 135-138
Closed Access | Times Cited: 40
Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature
Dominika Labochka, Barbara Moszczuk, Wojciech Kukwa, et al.
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 6, pp. 1887-1894
Open Access | Times Cited: 37
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia
Brittany M. Duggan, Kevin P. Foley, Brandyn D. Henriksbo, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 36
Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment
Chie Hotta-Iwamura, Kristin V. Tarbell
Journal of Leukocyte Biology (2016) Vol. 100, Iss. 1, pp. 65-80
Open Access | Times Cited: 34
Mast cell activation disease and the modern epidemic of chronic inflammatory disease
Lawrence B. Afrin
Translational research (2016) Vol. 174, pp. 33-59
Closed Access | Times Cited: 33
Coronary atherosclerosis and chemotherapy: From bench to bedside
Fanghui Zhou, Xinxin Zhu, Yao Liu, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 10
Exploiting the promiscuity of imatinib
Shun J. Lee, Jean Y. J. Wang
Journal of Biology (2009) Vol. 8, Iss. 3, pp. 30-30
Open Access | Times Cited: 43
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes
Dariush Mokhtari, Nils Welsh
Clinical Science (2009) Vol. 118, Iss. 4, pp. 241-247
Closed Access | Times Cited: 41
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
John J. Powers, Jason A. Dubovsky, Pearlie K. Epling‐Burnette, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2011) Vol. 52, Iss. 4, pp. 668-679
Open Access | Times Cited: 39
Lymphangiogenesis Is Required for Pancreatic Islet Inflammation and Diabetes
Na Yin, Nan Zhang, Girdhari Lal, et al.
PLoS ONE (2011) Vol. 6, Iss. 11, pp. e28023-e28023
Open Access | Times Cited: 37
Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?
Brett E. Phillips, Massimo Trucco, Nick Giannoukakis
Clinical and Developmental Immunology (2011) Vol. 2011, pp. 1-18
Open Access | Times Cited: 34
Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl
Dariush Mokhtari, Rasel A. Al-Amin, Kyril Turpaev, et al.
Diabetologia (2013) Vol. 56, Iss. 6, pp. 1327-1338
Open Access | Times Cited: 33
Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function
S. Armando Villalta, Jiena Lang, Samantha Kubeck, et al.
Diabetes (2013) Vol. 62, Iss. 8, pp. 2870-2878
Open Access | Times Cited: 33
Combination Immunotherapy for Type 1 Diabetes
Robert N. Bone, Carmella Evans‐Molina
Current Diabetes Reports (2017) Vol. 17, Iss. 7
Open Access | Times Cited: 31
Novel cancer therapies and their association with diabetes
Afreen Shariff, Sohail Syed, Rebecca A. Shelby, et al.
Journal of Molecular Endocrinology (2018) Vol. 62, Iss. 2, pp. R187-R199
Open Access | Times Cited: 30

Scroll to top